Skip to main content

Table 1 LLC cell DHA metabolite concentration (ng/105 cell) determined by LC-MS/MS

From: Inhibition of lung cancer growth and metastasis by DHA and its metabolite, RvD1, through miR-138-5p/FOXC1 pathway

OxylipinLLC-GFPLLC-GFP treat with DHALLC-mfat-1
10-HDoHE0.34 ± 0.201072.73 ± 245.41**736.22 ± 205.21**
10S,17S-DiHDoHENP8.75 ± 3.54**NP
11-HDoHENP1300.73 ± 254.98**NP
13-HDoHE0.56 ± 0.39734.25 ± 261.61**575.98 ± 272.13**
14-HDoHE0.46 ± 0.32454.98 ± 197.20*179.32 ± 92.18**
17-HDoHE1.31 ± 0.741674.18 ± 492.10**661.26 ± 133.4**
20-HDoHE1.00 ± 0.632567.3 ± 438.31**822.19 ± 212.35**
4-HDoHE2.93 ± 1.105175.27 ± 475.64**1634.9 ± 773.01**
7-HDoHE0.59 ± 0.342020.17 ± 293.62**536.16 ± 124.03**
8-HDoHE2.57 ± 1.655847.24 ± 425.41**1298.76 ± 235.18**
MaresinNPNPNP
RvD1NP2.18 ± 0.59**1.07 ± 0.32**
RvD2NPNPNP
16,17-EDP0.76 ± 0.551079.19 ± 333.12**343.23 ± 83.43**
19,20-EDP1.43 ± 0.423858.48 ± 419.96**1131.8 ± 241.57**
  1. *P < 0.05, **P < 0.01 compared with LLC-GFP. Data are mean ± SD. NP No peak, CYP Cytochrome P450 enzymes, COX Cyclooxygenase, LOX Lipoxygenase, PG Prostaglandin